Caelyx Adjuvant in Elderly Breast Cancer

• ClinicalTrials.gov Identifier: NCT00284336
• Recruitment Status: Completed
• First Posted: January 31, 2006
• Last Update Posted: December 9, 2014
• Sponsor: Universitaire Ziekenhuizen Leuven
• Information provided by (Responsible Party): prof. dr. Hans Wildiers, Universitaire Ziekenhuizen Leuven

Study Description

Brief Summary:

This is an open label Phase II study in elderly patients (65y or older) with early breast cancer who are candidate for adjuvant chemotherapy. A scheme with liposomal doxorubicin (Caelyx) and cyclophosphamide (endoxan) will be used. The aim is to study the cardiac effects of liposomal doxorubicin with new non-invasive techniques, ie strain rate imaging, classical echocardiography, and special blood tests measuring troponin I and BNP.

Condition or disease	Intervention/treatment	Phase
Breast Cancer; Elderly	Drug: Caelyx; Drug: endoxan	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Enrollment: 16 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open Label Phase II Trial to Investigate the Cardiac Effects of Pegylated Liposomal Doxorubicine (Caelyx) in Elderly Breast Cancer Patients With New Imaging and Biochemical Techniques.
• Study Start Date: January 2006
• Study Completion Date: April 2007

Arms and Interventions

Intervention Details:

• Drug: Caelyx
  Other Name: liposomal doxorubicin
• Drug: endoxan
  Other Name: cyclophosphamide

Outcome Measures

Primary Outcome Measures :

1. Investigate the effect on cardiac strain rate imaging (SRI) of Caelyx
2. The relation between cardiac SRI and classical ejection fraction measurement.
3. The relation between strain rate and blood markers such as troponin-I and BNP

Secondary Outcome Measures :

1. To assess the tolerability of Caelyx containing regimens in elderly breast cancer patients.

Eligibility Criteria

• Ages Eligible for Study: 65 Years and older (Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically proven early breast cancer requiring adjuvant chemotherapy according to the treating physician (lymph node positive or other features of high risk according to St-Gallen criteria).
• Age > 65 years
• Normal cardiac function (assessment of LVEF by MUGA scan or echocardiography above the lower limit of normal for the institution).
• Performance status 0 to 2 (WHO scale)
• The determination of ER and PgR is mandatory (immunohistochemical methods required; ER and/or PgR positivity is defined as > 1% of positive cells). Also determination of Her2neu is mandatory, either by immunohistochemistry or by FISH
• Adequate organ function (as defined by neutrophils > 1.5 x109/L, Platelets > 100 x 109/L, Hemoglobin > 10 g/dl, total bilirubin > 1.5 UNL, ASAT (SGOT) and ALAT (SGPT) > 1.5 UNL, alkaline phosphatase > 2.5 UNL, creatinine > 1.5 mg/dl (150 µmol/L)
• Complete staging work-up within 2 months prior to registration. All patients will have bilateral mammography, chest X-ray (PA and lateral) and/or CT-scan, abdominal ultrasound and/or CT scan, bone scan. In case of positive bone scan suspicious for metastases, bone X-ray (or bone CT-scan on spinal hot spots) is mandatory to rule out the possibility of metastatic disease. Other tests may be performed as clinically indicated.
• Patients must be accessible for treatment and follow-up.
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
• Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

• Metastatic disease (M1)
• Prior systemic anticancer therapy for breast cancer (chemotherapy, hormone therapy of immunotherapy)
• Prior radiation therapy for breast cancer.
• Pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI criteria.

• Serious illness or medical condition:

  • Congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrythmias
  • History of significant neurological or psychiatric disorders that would prohibit the understanding and giving of informed consent.
  • Active uncontrolled infection
  • Active peptic ulcer, unstable diabetes.
• Past (less than 5 years) or current history of other neoplasm except for curatively treated basal cell skin cancer or in situ carcinoma of the cervix.
• Concurrent treatment with hormonal replacement therapy: this treatment should be stopped at least 15 days before study entry
• Concurrent treatment with other experimental drugs. No participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
• Concurrent treatment with any other anti-cancer therapy.

Contacts and Locations

Locations

Belgium

UZ gent

Gent, Belgium, 9000

UH gasthuisberg

Leuven, Belgium, 3000

Sponsors and Collaborators

Universitaire Ziekenhuizen Leuven

Investigators

• Principal Investigator: hans wildiers, MD PhD; UH gasthuisberg Leuven

More Information

• Responsible Party: prof. dr. Hans Wildiers, adjunct head of clinic, Universitaire Ziekenhuizen Leuven
• ClinicalTrials.gov Identifier: NCT00284336
• Other Study ID Numbers: 2005-002995-13; S28720 UZ KUL
• First Posted: January 31, 2006
• Last Update Posted: December 9, 2014
• Last Verified: December 2014

Keywords provided by prof. dr. Hans Wildiers, Universitaire Ziekenhuizen Leuven:

breast cancer; elderly; adjuvant chemotherapy; Caelyx

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Cyclophosphamide; Doxorubicin; Liposomal doxorubicin; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Antibiotics, Antineoplastic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors